---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-000772"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:09:54.512072+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ardelyx reports preliminary Q4 2023 IBSRELA net sales of ~$28M, full year ~$80M, and XPHOZAH ~$2.5M

## Summary
- IBSRELA US net sales: Q4 ~$28M, FY2023 ~$80M (unaudited).
- XPHOZAH US net sales: Q4 ~$2.5M (unaudited).
- Cash and investments ~$184M as of Dec 31, 2023 (unaudited).

## SEC filing metadata
- accession: 0001628280-24-000772
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828024000772/0001628280-24-000772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828024000772/ardx-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-000772
- JSON: https://secwatch.observer/filing/0001628280-24-000772.json
- Plain text: https://secwatch.observer/filing/0001628280-24-000772.txt

## Key facts
- Earnings Releases
  ARDELYX, INC. reported the fourth quarter ended December 31, 2023 results: revenue approximately $28 million.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: approximately $28 million
  - Result: preliminary results
  source text: On January 8, 2024, Ardelyx, Inc. (the “Company”) announced unaudited U.S. net product sales revenue of IBSRELA ® (tenapanor) of approximately $28 million for the fourth quarter ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1437402/000162828024000772/0001628280-24-000772-index.htm
- Earnings Releases
  ARDELYX, INC. reported the full year ended December 31, 2023 results: revenue approximately $80 million.
  - Period: the full year ended December 31, 2023
  - Revenue: approximately $80 million
  - Result: preliminary results
  source text: On January 8, 2024, Ardelyx, Inc. (the “Company”) announced unaudited U.S. net product sales revenue of IBSRELA ® (tenapanor) of approximately $28 million for the fourth quarter ended December 31, 2023, and approximately $80 million for the full year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1437402/000162828024000772/0001628280-24-000772-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.